New Drugs 2018- Pharmacy Technician
Price
Credits
Format
In 2018, the US Food and Drug Administration (FDA) approved
59 new drugs – the highest number in more than
10 years – including 19 first-in-class agents.
Of the 59 new approvals, 73% received priority review. This issue
of The Rx Consultant focuses on the new drugs that may
be important additions (including a number of “firsts”)
in their therapeutic areas: influenza infection, HIV-1
infection, pneumonia and skin infections, nonmetastatic,
castration-resistant prostate cancer, endometriosis, migraine
prophylaxis, moderate to severe acne, and chronic,
idiopathic constipation.
Dosing and drug interactions
are detailed in Table 1. Brief descriptions of selected additional
new drugs are shown in Table 2, and new HIV
drugs and HIV drug combinations are decribed in Table
3. Table 4 lists selected new formulations or indications
for previously approved drugs.
